Entrada Therapeutics Inc Cash Flow Conversion Efficiency
Entrada Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has a cash flow conversion efficiency ratio of -0.139x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.46 Million) by net assets ($233.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Entrada Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Entrada Therapeutics Inc from 2019 to 2025. This chart illustrates how Entrada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Entrada Therapeutics Inc share price for real-time trading data and today's change.
Entrada Therapeutics Inc Cash Flow Conversion Ratio Explained
Entrada Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Entrada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entrada Therapeutics Inc ranked by their cash flow conversion efficiency. Also see TRDA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Arkora Hydro Tbk
JK:ARKO
|
-0.153x |
|
TechTarget, Inc. Common Stock
NASDAQ:TTGT
|
-0.015x |
|
ProQR Therapeutics BV
NASDAQ:PRQR
|
-0.156x |
|
Spurcorp
JSE:SUR
|
0.174x |
|
QuantaSing Group Limited American Depositary Shares
NASDAQ:QSG
|
0.061x |
|
Amcil Ltd
AU:AMH
|
0.008x |
|
Dream Office Real Estate Investment Trust
TO:D-UN
|
0.001x |
|
GTM Holdings Corp
TW:1437
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Entrada Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Entrada Therapeutics Inc from 2019 to 2025. Review Entrada Therapeutics Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $306.13 Million | $-128.51 Million | -0.420x | -333.03% |
| 2024-12-31 | $428.68 Million | $-41.56 Million | -0.097x | -116.81% |
| 2023-12-31 | $242.36 Million | $139.80 Million | 0.577x | +230.73% |
| 2022-12-31 | $212.55 Million | $-93.79 Million | -0.441x | -159.14% |
| 2021-12-31 | $298.72 Million | $-50.86 Million | -0.170x | -127.63% |
| 2020-12-31 | $-41.49 Million | $-25.57 Million | 0.616x | -11.46% |
| 2019-12-31 | $-15.52 Million | $-10.80 Million | 0.696x | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potent… Read more